NCI / CTEP Staff / Correlative Science Studies/Reference Laboratories / K. Maximizing Available Financial Resources / Operations Center / I. Intergroup / Other NCI Staff / Intergroup / /
Currency
USD / /
Event
Business Partnership / FDA Phase / Company Expansion / /
Facility
National Cancer Institute / Reference Laboratory / /
IndustryTerm
continuation applications / CANCER THERAPY / supplemental applications / CANCER TREATMENT / non-competing continuation applications / /
MedicalCondition
CANCER / conduct cancer / /
MedicalTreatment
chemotherapy / Cancer Therapy / /
Organization
National Cancer Institute / US Department of Health and Human Services / Congress / Division of Cancer Treatment and Diagnosis / Grants Administration / National Institute of Health / office of Human Research Protections / Awardee Organization / Quality Assurance Research Center / office of Grants Administration / Institutional Review Board / Statistics and Data Management Center / Radiological Physics Center / A. CTEP Staff Administration / SDMC Organization / C. Grants Management Administration / Executive Committee / SDMC / Chemotherapy National Service Center / Cancer Control and Prevention Committee / Awardee Institution / NCI Office / Office for Human Research Protection / Division of Extramural Activities / Data and Safety Monitoring Board / /
Person
Mary Lasker / Costs / Sidney Farber / /
Position
A. General / Program Director / Program Specialist / Principal Investigator / General Budget / Consultant / Project Scientist / Group Chair / General / /
Product
Development / /
Technology
21 1.2 Study/Protocol / 84 2.1 Study/Protocol / 31 2.2 Study/Protocol / Information Technology / chemotherapy / treating cancer / 41 3.1 Study/Protocol / Drug Development / /
NATIONAL CANCER INSTITUTE CLINICAL TRIALS COOPERATIVE GROUP PROGRAM GUIDELINES CANCER THERAPY EVALUATION PROGRAM